Get access

Treatment of essential tremor with the barbiturate t2000 (1,3-dimethoxymethyl-5,5-diphenyl-barbituric acid)


  • Calvin Melmed MD,

    1. Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec, Canada
    2. Department of Neurosciences, SMBD-Jewish General Hospital, Montreal, Quebec, Canada
    Search for more papers by this author
  • Daniel Moros MD,

    Corresponding author
    1. Taro Pharmaceuticals USA Inc., Hawthorne, New York, USA
    2. Department of Neurology, Mount Sinai School of Medicine, New York City, New York, USA
    • Taro Pharmaceuticals USA Inc., 3 Skyline Drive, Hawthorne, New York, NY 10532
    Search for more papers by this author
  • Howard Rutman MD

    1. Taro Pharmaceuticals USA Inc., Hawthorne, New York, USA
    2. Albert Einstein College of Medicine of Yeshiva University, Bronx, New York, USA
    Search for more papers by this author


The effect of the barbiturate T2000 (1,3-dimethoxymethyl-5,5-diphenyl-barbituric acid; DMMDPB) on essential tremor, given in twice daily doses of 400 and 300 mg, was assessed in two brief, randomized, placebo-controlled, parallel-group, double-blinded, single-center trials in 12 and 22 patients, respectively. These trials represent the first clinical use of T2000 for a specific indication. The primary endpoint was the change in the mean scores of the treated and control groups based on the Fahn-Tolosa-Marin tremor scale. In the first study of 12 patients treated with 400 mg or placebo twice daily for 14 days, the mean change from baseline at day 14 was 19.3 (P < 0.0001) in the treated group and 9.0 (P = 0.0121) in the control group. Using a two-factor mixed ANOVA model to evaluate within group and between group changes, the effect of T2000 was significantly different from that of the placebo group (P = 0.03). In the second study of 22 patients treated with 300 mg of T2000 or placebo twice daily for 20 days, statistically significant changes were seen in treated patients compared to baseline, but the ANOVA model did not demonstrate a significant treatment effect of T2000 compared to placebo. When the treated groups from each study are compared, the 800-mg daily group is significantly different from the 600-mg daily group (P = 0.02). Some treated patients in each study, but no placebo patients, experienced marked improvement. These results support further evaluation of T2000 in the treatment of essential tremor. © 2006 Movement Disorder Society